Abstract:
:Normal pregnancy is associated with increased insulin resistance as a metabolic adaptation to the nutritional demands of the placenta and fetus, and this is amplified in obese mothers. Insulin resistance is normally compensated for by an adaptive increase in pancreatic β-cell mass together with enhanced glucose-stimulated insulin release. Placentally-derived hormones and growth factors are central to the altered pancreatic morphology and function. A failure of β-cells to undergo adaptive change after the first trimester has been linked with gestational diabetes. In the pregnant mouse, an increase in β-cell replication contributes to a 2-3-fold increase in mass peaking in late gestation, depending on the proliferation of existing β-cells, the differentiation of resident progenitor β-cells, or islet cell transdifferentiation. Using mouse models and human studies placenta- and islet of Langerhans-derived molecules have been identified that are likely to contribute to the metabolic adaptations to pregnancy and whose physiology is altered in the obese, glucose-intolerant mother. Maternal obesity during pregnancy can create a pro-inflammatory environment that can disrupt the response of the β-cells to the endocrine signals of pregnancy and limit the adaptive changes in β-cell mass and function, resulting in an increased risk of gestational diabetes.
journal_name
Curr Vasc Pharmacoljournal_title
Current vascular pharmacologyauthors
Szlapinski SK,Hill DJdoi
10.2174/1570161118666200320111209subject
Has Abstractpub_date
2021-01-01 00:00:00pages
141-153issue
2eissn
1570-1611issn
1875-6212pii
CVP-EPUB-105412journal_volume
19pub_type
杂志文章abstract:BACKGROUND:Kallistatin (KS) is a serine proteinase. The result of KS on 'Renal Ischemia- Reperfusion Injury' (IRI) has not clearly been researched. In this study, investigative research has been conducted to draw results on the administration of human KS on kidney response conducted within a mouse model of IRI. MATERI...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161113666150204142716
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the general population. The disease ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma. Several drugs are used in daily clinical practice to manage the disease. However, dat...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161115666170621083744
更新日期:2018-01-01 00:00:00
abstract::Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) are idiopathic, intestinal and systemic inflammatory disorders which are immunologically mediated with the activation of plasma proteolytic cascades. The activation of coagulation in IBD is related to the activity and colonic extension of t...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016112801784495
更新日期:2012-09-01 00:00:00
abstract::Revascularization procedures used for the treatment of cardiovascular disease can be associated with restenosis, although drug-coated stents have greatly reduced this complication. Both type 2 diabetes (T2DM) and metabolic syndrome (MetS) are associated with a high risk for atherosclerosis and restenosis. Insulin resi...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016111795495558
更新日期:2011-05-01 00:00:00
abstract::In the last decade there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VA) and Sudden Cardiac Death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10-15% of SCD occurs in the presence of structurally ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016109788340794
更新日期:2009-07-01 00:00:00
abstract::There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161112666140613115813
更新日期:2014-01-01 00:00:00
abstract::Adipocytes are no longer considered just as cells related to storage of energy and thermoregulation. Now we know that they release a huge number of paracrine and endocrine biologically active molecules. This is also the case for perivascular adipose tissue (PVAT) that surrounds almost all blood vessels in the organism...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161112666140423220628
更新日期:2014-05-01 00:00:00
abstract::Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016110792006923
更新日期:2010-09-01 00:00:00
abstract:OBJECTIVE:To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment. METHODS:Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2174/1570161112666141014151858
更新日期:2015-01-01 00:00:00
abstract::Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulat...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016110790226679
更新日期:2010-01-01 00:00:00
abstract::Prostaglandins (PGs) belong to the family of prostanoids together with thromboxanes and are produced mainly from arachadonic acid by the enzyme cyclooxygenase. PGs are known to stimulate platelet aggregation, mediate inflammation and edema, play a role in bone metabolism and in biological adaptation of connective tiss...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161043476410
更新日期:2004-04-01 00:00:00
abstract:: ...
journal_title:Current vascular pharmacology
pub_type: 社论
doi:10.2174/1570161116666180713120217
更新日期:2019-01-01 00:00:00
abstract::Hypercoagulability is widely associated with sepsis, inflammation, diabetes, cancers, aging, and many pathological conditions, resulting in life-threatening disseminated intravascular coagulation (DIC), venous thrombosis, thromboembolism, cardiovascular complications, or even deadly multiple organ failure. Relieving c...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161043385673
更新日期:2004-07-01 00:00:00
abstract::The pathogenesis of obesity, insulin resistance and hypertension begins with an interaction between genetic factors and environmental factors. The search for the underlying genetic basis of these conditions has yielded disappointing results. It is possible that the importance of environmental influences has been under...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016106778521661
更新日期:2006-10-01 00:00:00
abstract::This review considers drug combinations and newer treatment strategies for patients with severe hypertriglyceridemia. Hypertriglyceridemia is associated with an atherogenic metabolic profile and in most studies with increased cardiovascular disease risk. Patients with severe hypertriglyceridemia also have increased in...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/15701611113119990133
更新日期:2014-01-01 00:00:00
abstract::Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosi...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161111311050013
更新日期:2013-09-01 00:00:00
abstract::This review demonstrates that oxidative stress, reactive oxygen species, and electron transfer can serve as unifying mechanistic themes for large numbers of cardiovascular toxins, both endogenous and exogenous. Lipid peroxidation is a prevalent insult. Common among the various conditions are atherosclerosis and arrhyt...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161053586912
更新日期:2005-04-01 00:00:00
abstract:BACKGROUND:Dyslipidaemia is a risk factor for macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. METHOD:A multicentre, non-interventional survey conducted in 6 Middle Eastern cou...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,多中心研究
doi:10.2174/1570161115666170705153815
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:The most common complications of chronic kidney disease (CKD) are hypertension and cardiovascular (CV) disorders. Renalase is produced and released by the kidney and also cardiomyocytes. Renalase deficiency was claimed to be responsible for hypertension and CV complication in CKD. There are contradictory dat...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161113666141217141805
更新日期:2015-01-01 00:00:00
abstract::Bladder outlet obstruction (BOO) is a common disorder that is associated with urinary tract symptoms. Nitric oxide (NO), synthesized by NO synthase (NOS) is a potent vasodilator that is present throughout the urinary tract and the corpus cavernosum. Endothelin-1 (ET-1) conversely is a potent vasoconstrictor peptide th...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161033386600
更新日期:2003-03-01 00:00:00
abstract::This review provides evidence that antenatal hypoxia, which represents a significant and worldwide problem, causes prenatal programming of the lung. A general overview of lung development is provided along with some background regarding transcriptional and signaling systems of the lung. The review illustrates that ant...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161111311050006
更新日期:2013-09-01 00:00:00
abstract:BACKGROUND:Add-on therapy with the Mineralocorticoid-Receptor-Antagonists (MRAs) spironolactone and eplerenone was shown to enhance the cardioprotective action of angiotensinconverting- enzyme-inhibitors (ACEIs), angiotensin-receptor-blockers (ARBs) and/or β-blockers in nondialysis patients with congestive heart failur...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161115666170201113817
更新日期:2017-01-01 00:00:00
abstract::Neuropathies of the peripheral and autonomic nervous systems affect up to half of all people with diabetes mellitus, and are major risk factors for foot ulceration, amputation and cardiovascular dysfunction. Peripheral neuropathies manifest with either painful or painless symptoms, but many patients experience both. O...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161117666190521101342
更新日期:2020-01-01 00:00:00
abstract::Nowadays long-term outcome of heart transplantation is limited by a peculiar type of coronary atherosclerosis, known as cardiac allograft vasculopathy (CAV). Although the exact pathogenesis of CAV remains unclear, emerging evidence indicates that the endothelium plays a significant role in the onset and progression of...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016110790886992
更新日期:2010-03-01 00:00:00
abstract::The recently published Assessment of Survival and Cardiovascular Events (AURORA) trial showed that rosuvastatin (10 mg/d) compared with placebo did not result in a significant reduction in vascular events despite a 43% fall in low density lipoprotein cholesterol (LDL-C) levels in patients with end-stage renal disease ...
journal_title:Current vascular pharmacology
pub_type: 社论,评审
doi:10.2174/157016109788340712
更新日期:2009-07-01 00:00:00
abstract::In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively. ...
journal_title:Current vascular pharmacology
pub_type: 评论,社论
doi:10.2174/157016112803520783
更新日期:2012-11-01 00:00:00
abstract::Platelet aggregation induced by stirring of a platelet suspension after activation by the exogenous addition of stimulants, such as ADP, epinephrine and thrombin, has long been used as a platelet function test, and for the screening of antiplatelet agents. Since platelet aggregation has been demonstrated to be mediate...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161043476456
更新日期:2004-01-01 00:00:00
abstract::Matrix metalloproteinases (MMP) comprise a family of at least 25 zinc-dependent endopeptidases that play a pivotal role in the physiopathology of the mammalian central nervous system. In the first phases after stroke, the dysregulation of MMPs has been described to increase acute neurovascular disruption and cerebral ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/15701611113116660161
更新日期:2015-01-01 00:00:00
abstract::Biomarkers are used in medicine to facilitate diagnosis, assess risk, direct therapy and determine efficacy of treatment. Sensitivity and specificity are essential in order for a biomarker to be useful. Brain natriuretic peptide (BNP) and C-reactive protein (CRP) are considered biomarkers of cardiovascular disease. Ho...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016107779317251
更新日期:2007-01-01 00:00:00
abstract:BACKGROUND:In the era of dual antiplatelet therapy of aspirin and clopidogrel and systematic stent implantation, Glycoprotein IIb/IIIa Inhibitors (GPI), including abciximab, eptifibatide and tirofiban, proved beneficial in improving early outcome of Percutaneous Coronary Intervention (PCI), especially in higher risk cl...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161116666180117102422
更新日期:2018-01-01 00:00:00